# Study of the Efficacy and Safety of Glufosfamide Compared With Best Supportive Care in Metastatic Pancreatic Cancer

> **NCT00099294** · PHASE3 · COMPLETED · sponsor: **Threshold Pharmaceuticals** · enrollment: 300 (—)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Glufosfamide

## Key facts

- **NCT ID:** NCT00099294
- **Lead sponsor:** Threshold Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** 2007-01
- **Final completion:** 2007-01
- **Target enrollment:** 300 (—)
- **Last updated:** 2009-04-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00099294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00099294, "Study of the Efficacy and Safety of Glufosfamide Compared With Best Supportive Care in Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT00099294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*